Category: catalyst-ligand

128143-89-5, 4′-Chloro-2,2′:6′,2”-terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of 40-Cltpy (26.7 mg, 0.100 mmol) in CH2Cl2(10 cm3) was added dropwise a methanolic solution (5 cm3) ofCoCl26H2O (23.7 mg, 0.100 mmol) at room temperature, theresulting green solution was stirred for 10 min, then filtered. Thefiltrate was allowed to slowly evaporate at room temperature for3 days, during which time green plates had formed and werecollected by decanting the solvent, washed with methanoland dried in air. Yield: 32.5 mg (81.7%). FT-IR (solid, cm1):1590s, 1553s, 1469s, 1415s, 1340w, 1290w, 1245 m, 1118s,1051w, 1016s, 898 m, 830s, 793s, 726 m, 687w, 634 m. Anal.Calc. C15H10Cl3CoN3 (397.55) requires: C, 45.32; H, 2.54; N, 10.57.Found: C, 45.33; H, 2.60; N, 10.54%.

The synthetic route of 128143-89-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Zhang, Guoqi; Tan, Jiawen; Zhang, Yuan Zhuo; Ta, Christine; Sanchez, Stephanie; Cheng, Shu-Yuan; Golen, James A.; Rheingold, Arnold L.; Inorganica Chimica Acta; vol. 435; (2015); p. 147 – 152;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103505-54-0,[2,2′-Bipyridine]-6,6′(1H,1’H)-dione,as a common compound, the synthetic route is as follows.

Example 1 [Ru(bpy)2(66’bpy(OH)2)][PF6]2.H2O A round bottom flask containing 30 mL of 1:1 ethanol:water was degassed with argon for 30 minutes. To the flask, 0.2260 g (1.201 mmol) 66’bpy(OH)2 and 0.4843 g (0.9999 mmol) Ru(bpy)2(Cl)2 were added. The reaction mixture was heated at 80 C. under argon for 12 h. The reaction mixture turned red in color. After heating, the reaction mixture was allowed to cool to room temperature and filtered to remove any insoluble, unreacted ligand. A few drops of concentrated HCl was added to the filtrate to ensure protonation and the solution was diluted to 200 mL with water. An aqueous solution of ammonium hexafluorophosphate was added to the filtrate to precipitate the complex as the hexafluorophosphate salt. The complex was filtered and rinsed with copious amounts of water and allowed to air dry overnight. Yield: 0.5738 g (0.6309 mmol), 63%. deltaH (300 MHz, CD3CN): delta 6 8.70 (broad), delta 8.50 (d, 2H), delta 8.35 (d, 2H), delta 7.95 (m, 10H), delta 7.55 (d, 2H), delta 7.45 (t, 2H), delta 7.20 (t, 2H), delta 6.70 (d, 2H). Elem. Anal: Found: C, 39.43; N, 9.23; H, 2.89%. Calc. for RuC30N6O2H24P2F12.H2O: C, 39.62; N, 9.24; H, 2.88%.

As the paragraph descriping shows that 103505-54-0 is playing an increasingly important role.

Reference£º
Patent; The Board of Trustees of the University of Alabama; Papish, Elizabeth T.; Paul, Jared J.; Merino, Edward J.; (21 pag.)US2016/101177; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[00132] To a solution of 1 -pyrenecarboxaldehyde (35 mg, 0.15 mmol) in 1 ml_ DCE, Boc3Cyclam (50 mg, 0.10 mmol) was added and stirred together with 4A molecular sieves for 2 h under nitrogen atmosphere. To this solution sodium triacetoxyborohydride (42 mg, 0.2 mmol) was added and the reaction mixture was allowed to stir at ambient temperature over 24 h under nitrogen atmosphere. Subsequently, the reaction mixture was diluted with sodium bicarbonate and extracted with DCM. The extract was purified by flash chromatography with 30% ethyl acetate/hexanes to give the product (63 mg, 88%); 1H NMR (400 MHz, CDC) delta 8.47 (d, J = 9.3 Hz, 1H), 8.21 – 7.93 (m, 8H), 4.22 (s, 2H), 3.34 (s, 10H), 3.13 (s, 2H), 2.78 (s, 2H), 2.50 (s, 2H), 1.88 (s, 2H), 1.76 – 1.66 (m, 2H), 1.51 – 1.17 (m, 27H); 13C NMR (100 MHz, CDCb) delta 155.55, 132.64, 131.33, 130.87, 130.77, 129.71, 128.41, 127.47, 127.10, 125.83, 125.00, 124.83, 124.50, 124.06, 79.67, 79.44, 58.59, 54.24, 53.43, 47.81, 47.07, 29.72, 28.50, 28.46, 28.31 ; LRMS (ESI+) m/z calc’d for CHssN-OeNa [M + Na]+ 737.42, found 737.65.

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; KRASKOUSKAYA, Dziyana; CABRAL, Aaron; MURCAR-EVANS, Bronte; TOUTAH, Krimo; DE ARAUJO, Elvin; (141 pag.)WO2019/68177; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step-2: Preparation of tetrabutylammonium salt of (2,S’,5ii)-2-[(6-sulfooxy-7-oxo-l,6- diaza-bicyclo[3.2.1]octane-2-carbonyl)-methyloxycarbamoyl]-(2,S’)-pyrrolidine-l- carboxylic acid tert-butyl ester: A solution of the Benzyl compound (2.1g, mmol) in 1: 1 mixture of DMF: DCM (5ml), was hydrogenated over 10% Pd/C (125mg) over 1 atmosphere of Hydrogen balloon. After stirring for 4 hours the reaction mixture was filtered over celite. The filtrate was concentrated under reduced pressure and the residue obtained was dissolved in fresh DMF (2.5ml) and cooled to 10C.SO3.DMF complex (193mg, 12.6mmol) was added and the reaction mixture was allowed to warm to RT. After stirring RM at RT for 1.5 hours, TBAA (379mg, 12.6mmol) in water (1.25ml) was added to the reaction mixture and stirring continued further for 2hours. The volatiles were removed by high vacuum distillation and the residue co-evaporated with xylene (2X25ml) to remove traces of DMF. The residue obtained was diluted with water (20ml) and extracted with DCM (3X20ml). The combined DCM layer was washed with water (2X20ml). The DCM layer was dried and the solvent evaporated under reduced pressure. The crude residue was triturated with Diethyl ether (3X25ml) to obtain the product as a white solid, 610mg, 82% yield. Analysis: Mass: 463.4 (M-H) for MW-705.96 and M.F- C33H63N509 S. XH NMR: Solvent(CDCl3): 10.2 (s, 1H), 4.35 (s, 1H), 4.14 (s, 1H), 3.91-3.92 (d, 2H), 3.74 (m, 1H), 3.36-3.27 (m, 10H), 2.96-2.88 (dd, 2H), 2.31-2.26 (m, 2H), 2.19-1.98 (m, 2H), 1.95-1.70 (m, 4H), 1.68-1.62 (p, 8H), 1.49-1.40 (m, 17H), 1.02-0.98 (t, 12H) .

As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

Reference£º
Patent; WOCKHARDT LIMITED; PATIL, Vijaykumar, Jagdishwar; TADIPARTHI, Ravikumar; DOND, Bharat; KALE, Amol; VELUPILLAI, Loganathan; DEKHANE, Deepak; BIRAJDAR, Satish, Shrimant; SHAIKH, Mohammad, Usman; MAURYA, Sushilkumar; PATEL, Piyush, Ambalal; DIXIT, Prasad; PAWAR, Mangesh; PATEL, Mahesh, Vithalbhai; BHAGWAT, Sachin; WO2014/33560; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1671-87-0,3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine,as a common compound, the synthetic route is as follows.

The reaction of 12 with 4 was monitored by UV-Vis, using a ten-fold excess of the dienophile. The reaction was conducted at 25 C. in a 1-mL UV cuvette. A 2¡Á10-5 M solution of compound 4 in THF and a 2¡Á10-4 solution of compound 12 in THF were prepared separately. A 0.5 mL portion of each solution was added to the cuvette, and measurements were taken every 10 seconds until complete consumption of 4.

The synthetic route of 1671-87-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; University of Delaware; US2009/23916; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

0.75 g (5.6 mmol) of 1,4,7-triazacyclononane was completely dissolved in 50 mL of ethanol, followed by 2.8 mL(20.2 mmol) triethylamine and 2.71 g (19.6 mmol) bromoacetamide, and the mixture was heated under reflux and stirred for 6 hours, then naturally cooled to room temperature, suction filtered, and the white solid obtained was vacuum dried at 35 C. to obtain the ligand represented by Formula I.

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Patent; Shaanxi Normal University; Liu Jing; Quan Jingmiao; Lei Hairui; Yan Junlin; (8 pag.)CN104892533; (2017); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

117330-40-2, Dimethyl 6,6′-dimethyl-[2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

In the absence of water,Under anaerobic conditions,1 mmol of 6,6-dimethyl-4,4-dimethyl-2,2-bipyridine (i.e., the compound represented by the formula (1-1)) was added to a 100 mL two-necked flask,Then add about 40 mL of anhydrous,Anaerobic toluene,Heated to 80 C,A t-BuOH solution of t-BuLi was added dropwise;After adding,The reaction was continued for 30 min,To give the compound 6,6-dimethyl-4,4-di-tert-butyl-2,2-bipyridine(I.e., the intermediates represented by formula (1-2)),Yield 58%.

As the paragraph descriping shows that 117330-40-2 is playing an increasingly important role.

Reference£º
Patent; Suzhou Institute of Biomedical Engineering Technology, Chinese Academy of Sciences; Liu, Yuanzhong; Wang, Bidou; Liu, Tao; Han, Kun; Luo, Gangyin; Cheng, Wenbo; Zhu, Nannan; (24 pag.)CN106432298; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a solution of benzyl (2-((((3,5-bis(trifluoromethyl)sulfonyl)oxy)-4,6-di-O- benzoyl-beta-D galactopyranosyl)oxy)ethyl)carbamate (16.9 g, 20.37 mmol) in anhydrous toluene (100 mL), was added a solution of tetra butylammonium acetate (25 g, 82.9 mmol) in a mixture of toluene (150 mL) and DMF (4 mL) was added and the resulting mixture stirred at room temperature overnight. Diluted with of CH2Cl2 (30 mL) and washed with sat. NaCl (2 x 100mL), dried over MgSO4, filtered and evaporated. The residue was purified by silica gel column chromatography (Teledyne Isco : 330g) eluent: 0-50% EtOAc / Hexane (10cv) then 50% EtOAc / Hexane (5cv) to give the title compound (8 g, 60.5%).1H NMR (CDCl3) delta 8.10 (2H, m), 7.98 (2H, dd, J = 8.1 and 1.4 Hz), 7.61 (2H, m), 7.48 (2H, t, J = 7.8 Hz), 7.46 (2H, t, J = 7.7 Hz), 7.37 (4H, m), 7.33 (1H, m), 5.70 (1H, d, J = 3.3 Hz), 5.61 (1H, t, J = 10.0 Hz), 5.29 (1H, dd, J = 10.0 and 3.3 Hz), 5.26 (1H, m), 5.10 (2H, s), 4.79 (1H, s), 4.64 (1H, dd, J = 12.1 and 2.7 Hz), 4.47 (1H, dd, J = 12.1 and 5.8 Hz), 3.94 (2H, m), 3.74 (1H, m), 3.48 (1H, m), 3.37 (1H, m), 2.15 (3H, s), 2.00 (3H, s).

As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; FENG, Danqing; GUIDRY, Erin, N.; HUO, Pei; KAARSHOLM, Niels, C.; LIN, Songnian; NARGUND, Ravi, P.; YAN, Lin; (233 pag.)WO2016/164288; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The product of Part 17B (131 mg, 0.250 mmol) was dissolved in 2:1 MeCN/H2O (5.00 mL) and successively treated with 14.2 mg TPPTS (25.0 mumol; 10 mol %), Et2NH (129 muL, 1.25 mmol) and 2.8 mg Pd(OAc)2 (12.5 mumol; 5 mol %) at 22 C. Complete deprotection was observed within 0.25 h. The resulting amber solution was then lyophilized to remove all volatile components. The solids thus obtained were redissolved in DMF and successively treated with HOBt (45.9 mg, 0.300 mmol), 2-(1,4,7,10-tetraaza-4,7,10-tris{[(tert-butyl)oxycarbonyl]methyl}-cyclododecyl)acetic acid (172 mg, 0.300 mmol), i-Pr2NEt (105 muL, 0.600 mmol) and HBTU (114 mg, 0.300 mmol) at 22 C. After 0.25 h, complete acylation was observed; only trace amounts of regioisomeric and dimeric products formed. The resulting solution was partitioned between EtOAc and H2O (50 mL each) with transfer to a separatory funnel. The layers separated and the aqueous layer washed with EtOAc (2¡Á50 mL). The EtOAc solution was further washed with 0.1 M NaOH (3¡Á50 mL) and saturated aqueous NaCl (3¡Á50 mL each), then dried over MgSO4, filtered and concentrated in vacuo to a pale yellow oil that was used without further purification in the subsequent deprotection step. The protected conjugate (0.250 mmol theoretical) was dissolved in dioxane (2.50 mL) then successively treated with H2O (23 muL) and HCl (10.0 mmol; 2.50 mL of a 4 M solution in dioxane) at 22 C. The resulting pale yellow solution was stirred 17 h, during which time a heavy white precipitate formed. Upon complete deprotection, the volatiles were removed under a stream of N2 and the white solid residue redissolved in H2O containing 0.1% TFA (8.00 mL) then partially purified by HPLC on a Phenomenex Luna C18 column (21.2¡Á250 mm) using a 2%/min gradient from 0-60% MeCN containing 0.1% TFA and 10% H2O at 20 mL/min. The main product peak eluting at 21 min was collected and lyophilized to a white powder. Final purification was performed using the identical column and method. The main product peak was collected and lyophilized to a white powder (0.110 g, 97.3 mumol; 38.9%).

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Cesati, Richard R.; Harris, Thomas D.; Robinson, Simon P.; Looby, Richard J.; Cheesman, Edward H.; Yalamanchili, Padmaja; Casebier, David S.; (86 pag.)US9266846; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3030-47-5, N1-(2-(Dimethylamino)ethyl)-N1,N2,N2-trimethylethane-1,2-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of N,N,N?,N?-tetramethylethylene diamine or N,N,N?,N”,N”-pentamethyldiethylene triamine (1 mol) and 1, 3-propanesultone (2.1 mol) in CH3CN was stirred at room temperature for 48 h. On completion,the formed white crystal were filtered and washed with diethylether (3 ¡Á 20 mL), then dried under vacuum at 70 C for 8 h, L1 and L2 were obtained with yields of 95% and 97%, respectively.

3030-47-5 N1-(2-(Dimethylamino)ethyl)-N1,N2,N2-trimethylethane-1,2-diamine 18196, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Li, Xinzhong; Cao, Rong; Lin, Qi; Catalysis Communications; vol. 63; (2015); p. 79 – 83;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI